medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2021, Number 3

<< Back Next >>

Rev ADM 2021; 78 (3)

Role of oral tissues in SARS-CoV-2 infection.

Ortiz LL?, Morales LLA, Palazuelos RDF, Lam RJF, Castillo DLA

Language: Spanish
References: 42
Page: 167-175
PDF size: 221.30 Kb.


ABSTRACT

The COVID-19 pandemic caused by the SARS-CoV-2 virus is currently a global healthcare problem. The onset of this disease can exhibit several clinical manifestations ranging from mild to severe symptoms, depending on the individual's immune response. COVID-19 primarily affects the lungs by developing the Severe Acute Respiratory Syndrome (SARS) and the "cytokine storm", an exacerbated inflammatory reaction that can lead to multiorgan failure and consequently death. The angiotensin-converting enzyme 2 (ACE-2), present in several tissues in the human body, is known to act as the functional receptor of the SARS-CoV-2 germ facilitating its entrance into the cells. Such receptor is also present in diverse oral cavity tissues, indicating a latent route of infection due to its influence in the transmission mechanism by inhalation, either oral or nasal, of virus particles. Also, viral load in saliva and taste disorder symptoms like ageusia could indicate a viral infection in its early stages. This article presents evidence suggesting that several tissues in the oral cavity can be considered potential sites of SARS-CoV-2 infection, thus playing an essential role in the transmission mechanism and development of co-infections.


REFERENCES

  1. Rehman MFU, Fariha C, Anwar A, Shahzad N, Ahmad M, Mukhtar S et al. Novel coronavirus disease (COVID-19) pandemic: a recent mini review. Comput Struct Biotechnol J. 2021; 19: 612-623.

  2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20 (5): 533-534.

  3. A Chen Y, A Liu Q, A Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020; 92 (4): 418-423.

  4. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020; 24: 91-98.

  5. García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020; 11: 1441.

  6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506.

  7. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288: 192-206.

  8. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021; 17 (1): 8-19.

  9. Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021; 892: 173751.

  10. Herrera D, Serrano J, Roldán S, Sanz M. Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin Oral Investig. 2020; 24 (8): 2925-2930.

  11. Sakaguchi W, Kubota N, Shimizu T, Saruta J, Fuchida S, Kawata A et al. Existence of SARS-CoV-2 entry molecules in the oral cavity. Int J Mol Sci. 2020; 21 (17): 6000.

  12. Kanjanaumporn J, Aeumjaturapat S, Snidvongs K, Seresirikachorn K, Chusakul S. Smell and taste dysfunction in patients with SARS-CoV-2 infection: a review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac J Allergy Immunol. 2020; 38 (2): 69-77.

  13. Li Liu QW, Xavier Alvarez, Haibo Wang, Yanhua Du, Hua Zhu, Hong Jiang et al. Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol. 2011; 85 (8): 4025-4030.

  14. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12 (4): 372.

  15. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579 (7798): 270-273.

  16. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20 (6): 363-374.

  17. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021; 74 (1): 168-184.

  18. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12 (1): 8.

  19. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203 (2): 631-637.

  20. Ulrich H, Pillat MM, Tárnok A. Dengue Fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. Cytometry A. 2020; 97 (7): 662-667.

  21. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020; 35 (3): 266-171.

  22. Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother. 2020; 16 (12): 3055-3060.

  23. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020; 5 (10): 1185-1191.

  24. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020; 87: 18-22.

  25. Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, Acevedo AC, De Luca Canto G, Sugaya N et al. Oral manifestations in patients with COVID-19: a living systematic review. J Dent Res. 2020: 100 (2): 141-154.

  26. Bao L, Zhang C, Dong J, Zhao L, Li Y, Sun J. Oral microbiome and SARS-CoV-2: beware of lung co-infection. Front Microbiol. 2020; 11: 1840.

  27. Cruz Tapia RO, Peraza Labrador AJ, Guimaraes DM, Matos Valdez LH. Oral mucosal lesions in patients with SARS-CoV-2 infection. Report of four cases. Are they a true sign of COVID-19 disease? Spec Care Dentist. 2020; 40 (6): 555-560.

  28. Li YQ, Ren B, Peng X, Hu T, Li JY, Gong T et al. Saliva is a non-negligible factor in the spread of COVID-19. Mol Oral Microbiol. 2020; 35 (4): 141-145.

  29. Baghizadeh Fini M. Oral saliva and COVID-19. Oral Oncol. 2020; 108:104821.

  30. Vinayachandran D, Balasubramanian S. Salivary diagnostics in COVID-19: Future research implications. J Dent Sci. 2020; 15 (3): 364-366.

  31. Tuan P, Horby P, Dinh P, Mai L, Zambon M, Shah J et al. SARS transmission in Vietnam outside of the healthcare setting. Epidemiol Infect. 2007; 135 (3): 392-401.

  32. Warabi Y, Tobisawa S, Kawazoe T, Murayama A, Norioka R, Morishima R et al. Effects of oral care on prolonged viral shedding in coronavirus disease 2019 (COVID-19). Spec Care Dentist. 2020; 40 (5): 470-474.

  33. Dos Santos JA, Normando AGC, da Silva RLC, De Paula RM, Cembranel AC, Santos-Silva AR et al. Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations? Int J Infect Dis. 2020; 97: 326-328.

  34. Chandran R, Feller L, Lemmer J, Khammissa RAG. HIV-associated oral mucosal melanin hyperpigmentation: a clinical study in a South African population sample. AIDS Res Treat. 2016; 2016: 8389214.

  35. Corchuelo J, Ulloa FC. Oral manifestations in a patient with a history of asymptomatic COVID-19: case report. Int J Infect Dis. 2020; 100: 154-157.

  36. Galván CCC, Carretero HA, Rodríguez-Jiménez G, Fernández-Nieto P, Rodríguez-Villa LD, Navarro FA et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183 (1): 71-77.

  37. Anne-Gaelle Chaux-Bodard SD, Aline Desoutter. Oral manifestation of COVID-19 as an inaugural symptom? J Oral Med Oral Surg. 2020; 26 (2): 18.

  38. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, Jané-Salas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021; 27 (Suppl. 3): 710-712.

  39. Dziedzic A, Wojtyczka R. The impact of coronavirus infectious disease 19 (COVID-19) on oral health. Oral Dis. 2021; 27 (Suppl 3): 703-706.

  40. Diaz RM, Jimenez RA, Villarroel M. Oral manifestations associated with COVID-19. Oral Dis. 2021. Available in: https://doi.org/10.1111/odi.13555.

  41. Millsop JW, Wang EA, Fazel N. Etiology, evaluation, and management of xerostomia. Clin Dermatol. 2017; 35 (5): 468-476.

  42. Al-Khatib A. Oral manifestations in COVID-19 patients. Oral Dis. 2021; 27: 779-780.




2020     |     www.medigraphic.com